Results 101 to 110 of about 9,196 (170)

Hypothalamic Atrophy and Textural Changes in Polyglutamine Ataxias. [PDF]

Cerebellum
Rodrigues L, Rezende TJR, Martinez ARM, Massuyama B, Pedroso JL, Barsottini OGP, Iglesias JE, Appenzeller S, Rittner L, França MC.   +9 more
europepmc   +1 more source

The Status and Future Directions of Treatments for Polyglutamine Spinocerebellar Ataxia: A Bibliometric and Visual Analysis. [PDF]

Curr Neuropharmacol
Ding S, Peng L, Chen Z, Dong M, Tang C, Gong Y, He L, Wu Q, Qiu R, Jiang H.   +9 more
europepmc   +1 more source

Selective silencing of expanded CAG repeats: Chemically modified siRNA advances RNA-based therapies for polyglutamine diseases. [PDF]

Mol Ther Nucleic Acids
Scholten GJ, Hyde JT, Buijsen RAM.
europepmc   +1 more source

The Hsp40 cochaperone DNAJC7 regulates polyglutamine aggregation and exhibits context-dependent effects on polyglycine aggregation. [PDF]

J Biol Chem
Ramani B, Ehsani K, Kampmann M.
europepmc   +1 more source

Lipid Composition Drives Mutant Huntingtin Dimerization and Membrane Association: Insights from Computational Simulations. [PDF]

Molecules
Nicoara C, Criscuolo E, De Cristofaro A, Fezza F, Maccarrone M.   +4 more
europepmc   +1 more source

Tandem repeats in human brain evolution and disease susceptibility. [PDF]

Mol Cells
Lee H, An JY.
europepmc   +1 more source

842. RNAi Therapy for Polyglutamine Expansion Disorders [PDF]

Molecular Therapy, 2011
openaire   +1 more source

Dynamics of autophagy in response to high linear energy transfer radiation and cancer. [PDF]

Korean J Clin Oncol
Lal M.
europepmc   +1 more source

Non-coding RNAs in polyglutamine disorders: friend or foe?

Journal of Biosciences, 2008
Sonali, Sengupta, Subramaniam, Ganesh
openaire   +2 more sources

Surface-Engineered Precision Nano-Systems for Targeted Treatment of Huntington's Disease: A Review of Recent Advancements. [PDF]

Int J Nanomedicine
Zhang J, Nie L, Ma J, Wang X.
europepmc   +1 more source